Use of PARP Inhibitors for Ovarian Cancer

被引:2
|
作者
Armstrong, Deborah K. [1 ]
机构
[1] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, 1650 Orleans St,Room 190, Baltimore, MD 21231 USA
来源
关键词
MAINTENANCE THERAPY; DOUBLE-BLIND; BEVACIZUMAB; CARCINOMA; RUCAPARIB;
D O I
10.6004/jnccn.2021.5013
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PARP inhibitors have been used to treat numerous diseases, but these agents have been approved the longest for use in ovarian cancer. All trials of PARP inhibitor maintenance in newly diagnosed ovarian cancer are positive for prolonged progression-free survival (PFS), but patients with BRCA mutations consistently derive the most benefit. Testing for homologous recombination deficiency may provide information regarding the degree of PFS benefit. In individuals without a BRCA mutation, PARP inhibition also prolongs PFS after chemotherapy for platinum-sensitive, PARP-naive disease. As in the up-front setting, patients with BRCA mutations derive the most benefit in these trials. Finally, PARP inhibitors are active as monotherapy in PARP-naive, BRCA-mutated relapsed disease, with increased activity observed in platinum-sensitive versus platinumresistant disease.
引用
收藏
页码:636 / 638
页数:3
相关论文
共 50 条
  • [31] Clinical development of PARP inhibitors in ovarian cancer
    Fujiwara, Keiichi
    [J]. ANNALS OF ONCOLOGY, 2022, 33 : S447 - S447
  • [32] Latest development of PARP inhibitors in ovarian cancer
    Harano, Kenichi
    [J]. ANNALS OF ONCOLOGY, 2019, 30
  • [33] PARP inhibitors for targeted treatment in ovarian cancer
    Dizon, Don S.
    [J]. LANCET, 2017, 390 (10106): : 1929 - 1930
  • [34] Using PARP Inhibitors in Advanced Ovarian Cancer
    O'Cearbhaill, Roisin E.
    [J]. ONCOLOGY-NEW YORK, 2018, 32 (07): : 339 - 343
  • [35] PARP inhibitors in the treatment of ovarian cancer: a review
    Washington, Christina R.
    Moore, Kathleen N.
    [J]. CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2021, 33 (01) : 1 - 6
  • [36] PARP inhibitors and quality of life in ovarian cancer
    Aoki, Daisuke
    Chiyoda, Tatsuyuki
    [J]. LANCET ONCOLOGY, 2018, 19 (08): : 1012 - 1014
  • [37] The Current Landscape of PARP Inhibitors in Ovarian Cancer
    Camille C. Gunderson
    Britt K. Erickson
    Megan E. Buechel
    Kathleen N. Moore
    [J]. Current Obstetrics and Gynecology Reports, 2018, 7 (1) : 20 - 27
  • [38] Appropriate Selection of PARP Inhibitors in Ovarian Cancer
    Smith, Maria
    Pothuri, Bhavana
    [J]. CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2022, 23 (06) : 887 - 903
  • [39] Appropriate Selection of PARP Inhibitors in Ovarian Cancer
    Maria Smith
    Bhavana Pothuri
    [J]. Current Treatment Options in Oncology, 2022, 23 : 887 - 903
  • [40] Using PARP Inhibitors in the Treatment of Patients With Ovarian Cancer
    Kurnit, Katherine C.
    Coleman, Robert L.
    Westin, Shannon N.
    [J]. CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2018, 19 (12)